Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-04-15
2008-04-15
Yaen, Christopher (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S091100
Reexamination Certificate
active
07358351
ABSTRACT:
To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
REFERENCES:
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5437865 (1995-08-01), Garin-Chesa et al.
patent: 5811522 (1998-09-01), Wallace et al.
patent: 6090930 (2000-07-01), Wallace et al.
patent: 6217868 (2001-04-01), Wallace et al.
patent: 6380362 (2002-04-01), Watson et al.
patent: 6391302 (2002-05-01), Wallace et al.
patent: 19820190 (1999-11-01), None
patent: 1074617 (2001-02-01), None
patent: WO 93/25669 (1993-12-01), None
patent: WO 98/37094 (1998-08-01), None
patent: WO 98/45435 (1998-10-01), None
patent: WO 99/54443 (1999-10-01), None
patent: WO 99/55858 (1999-11-01), None
patent: WO 00/69884 (2000-11-01), None
patent: WO 01/09317 (2001-02-01), None
patent: WO 01/48192 (2001-07-01), None
patent: WO 01/53455 (2001-07-01), None
patent: WO 01/54474 (2001-08-01), None
patent: WO 01/55201 (2001-08-01), None
patent: WO 01/55317 (2001-08-01), None
patent: WO 01/55320 (2001-08-01), None
patent: WO 01/55441 (2001-08-01), None
patent: WO 01/57182 (2001-08-01), None
patent: WO 01/57190 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/90304 (2001-11-01), None
patent: WO 01/90357 (2001-11-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/02055 (2002-01-01), None
patent: WO 02/10217 (2002-02-01), None
patent: WO 02/10449 (2002-02-01), None
patent: WO 02/24956 (2002-03-01), None
Overbeek (1994, “Factors affectig transgenic animal production,” Transgenic animal technology, pp. 96-98).
Wall, 1996 Theriogenology, vol. 45, pp. 57-68.
Houdebine, 1994, J. Biotech. vol. 34, pp. 269-287.
Kappell, 1992, Current Opinions in Biotechnology, vol. 3, pp. 548-553.
Cameron, 1997, Molec. Biol. 7, pp. 253-265.
Niemann, 1997, Transg. Res. 7, pp. 73-75.
Mullins (1993, Hypertension, vol. 22, pp. 630-633).
Mullins (1990, Nature, vol. 344, 541-544.
Hammer (1990, Cell, vol. 63, 1099-1112.
Mullins, 1989, EMBO J., vol. 8, pp. 4065-4072.
Taurog, 1988, Jour. Immunol., vol. 141, pp. 4020-4023.
Mullins (1996, J. Clin. Invest. vol. 98, pp. S37-S40).
Rettig et al (PNAS USA Nov. 1992; 89:10832-10836).
Jansen, M et al, 1995, Pediatric Res, 37 (6): 681-686).
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Shantz and Pegg (Int J of Biochem and Cell Biol., 1999, vol. 31, pp. 107-122).
McClean and Hill (Eur J of Cancer, 1993, vol. 29A, pp. 2243-2248).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Yokota, J et al (Oncogene, 1988,vol. 3, pp. 471-475).
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990.
Reiger et al (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976).
Christian, S. et al., “Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium,”J. Bio. Chem., (Mar. 9, 2001), vol. 276, No. 10, pp. 7408-7414.
Rettig, W. et al., “Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer,”Proc. Natl. Acad. Sci. USA, (Nov. 1992), vol. 89, pp. 10832-10836.
Kinzler Kenneth W.
St. Croix Brad
Vogelstein Bert
Banner & Witcoff , Ltd.
The Johns Hopkins University
Yaen Christopher
LandOfFree
Endothelial cell expression patterns does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endothelial cell expression patterns, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelial cell expression patterns will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2796648